Cargando…

A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer

Transforming growth factor β (TGF-β) plays an important role in cancer. Monoclonal antibodies (mAb) designed to specifically block the TGF-β ligands, are expected to inhibit tumor progression in patients with metastatic cancer. TβM1 is a humanized mAb optimized for neutralizing activity against TGF-...

Descripción completa

Detalles Bibliográficos
Autores principales:	COHN, ALLEN, LAHN, MICHAEL M., WILLIAMS, KRISTEN E., CLEVERLY, ANN L., PITOU, CELINE, KADAM, SUNIL K., FARMEN, MARK W., DESAIAH, DURISALA, RAJU, ROBERT, CONKLING, PAUL, RICHARDS, DONALD
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2014
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215585/ https://www.ncbi.nlm.nih.gov/pubmed/25270361 http://dx.doi.org/10.3892/ijo.2014.2679

Ejemplares similares

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
por: Rodón, Jordi, et al.
Publicado: (2014)

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer
por: Gueorguieva, Ivelina, et al.
Publicado: (2016)

A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors
por: Becerra, Carlos R., et al.
Publicado: (2014)

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
por: Herbertz, Stephan, et al.
Publicado: (2015)

Deviation in the predefined calibration factors of the dose calibrators and the associated inaccuracy in the radioactivity measurements of beta-gamma emitters
por: Sharma, Sarika, et al.
Publicado: (2015)

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study
por: Kovacs, Richard J., et al.
Publicado: (2014)

First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti–IL-20 Monoclonal Antibody in Patients with Psoriasis
por: Gottlieb, Alice B., et al.
Publicado: (2015)

Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma
por: Boutros, Celine, et al.
Publicado: (2020)

Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial
por: Liu, Dan, et al.
Publicado: (2022)

Individualized chemotherapy drug dose escalation in dogs with multicentric lymphoma
por: Siewert, Jacob M., et al.
Publicado: (2023)

Dose escalation of a curcuminoid formulation
por: Lao, Christopher D, et al.
Publicado: (2006)

Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors
por: Bauer, Todd M, et al.
Publicado: (2023)

Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebo-controlled, dose-escalation phase 1 trial
por: Dai, Zhijie, et al.
Publicado: (2023)

Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors
por: Denlinger, Crystal S., et al.
Publicado: (2021)

Indirect Recognition of Predefined Human Activities
por: Majidzadeh Gorjani, Ojan, et al.
Publicado: (2020)

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019)

Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary
por: Ball, Susan G, et al.
Publicado: (2013)

Radiation treatment planning with embedded dose escalation
por: Hrinivich, William T., et al.
Publicado: (2019)

The role of biological dose-escalation for pancreatic cancer
por: Bruynzeel, Anna M.E., et al.
Publicado: (2019)

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
por: Elganainy, Dalia, et al.
Publicado: (2018)

National trends in radiation dose escalation for glioblastoma
por: Wegner, Rodney E., et al.
Publicado: (2019)

Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023)

The Effect of Budesonide/Formoterol Pressurized Metered-Dose Inhaler on Predefined Criteria for Worsening Asthma in Four Different Patient Populations with Asthma
por: Murphy, Kevin R., et al.
Publicado: (2012)

Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study: A Phase I Randomized, Controlled, Dose-Escalation Study
por: Petri, Michelle, et al.
Publicado: (2013)

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors
por: von Mehren, Margaret, et al.
Publicado: (2014)

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
por: Wheeler, Graham M.
Publicado: (2016)

Open‐Label, Dose‐Escalation, Phase 1 Study of Safety and Single and Multiple‐Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers
por: Cohen, Fredric
Publicado: (2018)

Erratum to: The effect of budesonide/formoterol pressurized metered-dose inhaler on predefined criteria for worsening asthma in four different patient populations with asthma
por: Murphy, Kevin R., et al.
Publicado: (2012)

Neural network dose prediction for rectal spacer stratification in dose‐escalated prostate radiotherapy
por: Thomas, Christopher, et al.
Publicado: (2022)

A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab
por: McKenzie, Andrew, et al.
Publicado: (2021)

Efficacy of Dose-Escalated Radiotherapy for Recurrent Colorectal Cancer
por: Jo, Sunmi, et al.
Publicado: (2016)

Dose‐escalation strategies which use subgroup information
por: Cotterill, Amy, et al.
Publicado: (2018)

Feasibility of Dose Escalation in Patients With Intracranial Pediatric Ependymoma
por: Tensaouti, Fatima, et al.
Publicado: (2019)

Safety and tolerability of escalating cannabinoid doses in healthy cats
por: Kulpa, Justyna E, et al.
Publicado: (2021)

Pharmacokinetics of escalating single‐dose administration of cannabidiol to cats
por: Rozental, Aaron J., et al.
Publicado: (2022)

Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis
por: Henderson, Robert D., et al.
Publicado: (2021)

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer
por: Sakiyama, T, et al.
Publicado: (2015)

Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors
por: Tsai, Hui-Jen, et al.
Publicado: (2021)

Phase 1 First-in-Human Dose Escalation and Dose Expansion Study of KLS-1 (64Zinc Aspartate) in Patients With Cancer and Neurodegenerative Diseases
por: Perez, Jesus A, et al.
Publicado: (2022)

De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation
por: Thomas, Pepijn W. A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_solitblo3nr6t4ol1n5f361fsu